13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
47 檔
48.1%
As reported in its official Q3 2025 Form 13F filing, Vivo Capital, LLC's tracked investment portfolio stood at $1.1B with 47 total positions.
In Q3 2025, Vivo Capital, LLC displayed an active expansion posture, initiating 15 new positions and adding to 10 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, VRNA, CDTX) accounted for 48.1% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 12.39% | -0.82% | EXIT | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 11.97% | — | — | |
| 3 | CDTX | Cidara Therapeutics Inc | Stock-Other | 10.11% | — | — | |
| 4 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.17% | -5.85% | EXIT | |
| 5 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.75% | +3.63% | +13.52% | |
| 6 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.30% | — | — | |
| 7 | COGT | Cogent Biosciences Inc | Stock-Other | 3.22% | -1.35% | EXIT | |
| 8 | SVA | Sinovac Biotech Ltd. | Stock-Other | 3.07% | +0.32% | — | |
| 9 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.02% | -0.12% | — | |
| 10 | GERN | Geron CORP | Stock-Other | 3.00% | -0.06% | — | |
| 11 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.69% | -2.65% | +57.95% | |
| 12 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.66% | +0.81% | +134.53% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.45% | +2.83% | — | |
| 14 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.45% | +0.19% | +99.39% | |
| 15 | TRML | Tourmaline Bio Inc | Stock-Other | 2.28% | — | — | |
| 16 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.11% | — | — | |
| 17 | VSTM | Verastem Inc | Stock-Other | 1.88% | — | +71.92% | |
| 18 | SABS | Sab Biotherapeutics Inc | Stock-Other | 1.85% | -1.04% | — | |
| 19 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.71% | -0.27% | EXIT | |
| 20 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.66% | — | — | |
| 21 | ERAS | Erasca Inc | Stock-Other | 1.63% | -9.44% | +37.25% | |
| 22 | RZLT | Rezolute Inc | Stock-Other | 1.60% | — | — | |
| 23 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.36% | +1.15% | — | |
| 24 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 1.33% | +0.42% | — | |
| 25 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.19% | -0.06% | — | |
| 26 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.12% | +0.68% | — | |
| 27 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.02% | +0.73% | — | |
| 28 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 0.95% | +0.13% | — | |
| 29 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.91% | — | — | |
| 30 | PEPG | Pepgen Inc | Stock-Other | 0.86% | +0.04% | — | |
| 31 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.85% | -1.87% | — | |
| 32 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.85% | -0.79% | +18.67% | |
| 33 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 34 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.74% | — | -50.00% | |
| 35 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 0.64% | — | — | |
| 36 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.63% | -0.74% | +57.42% | |
| 37 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.59% | +0.36% | — | |
| 38 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.53% | +0.19% | +29.45% | |
| 39 | DCTH | Delcath Systems Inc | Stock-Other | 0.49% | — | — | |
| 40 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.46% | — | — | |
| 41 | ETNBGBP | 89bio Inc | Stock-Other | 0.45% | — | — | |
| 42 | TIL | Instil Bio Inc | Stock-Other | 0.42% | +0.01% | — | |
| 43 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.41% | -0.01% | — | |
| 44 | SRZN | Surrozen Inc | Stock-Other | 0.27% | -0.01% | — | |
| 45 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.13% | +3.04% | — | |
| 46 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.08% | +0.01% | — | |
| 47 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +8.2% | — | Add |
| 2 | COGT | Cogent Biosciences Inc | +2.3% | +148.48% | Add |
| 3 | CMPX | Compass Therapeutics Inc | +1.8% | +57.95% | Add |
| 4 | 430 | Terns Pharmaceuticals Inc | +1.7% | — | Unchanged |
| 5 | ORIC | Oric Pharmaceuticals Inc | +1.5% | — | Add |
| 6 | DRUG | Bright Minds Biosciences Inc | +1.3% | +99.39% | Add |
| 7 | DYN | Dyne Therapeutics Inc | +1.1% | +134.53% | Add |
| 8 | TRML | Tourmaline Bio Inc | +1.1% | — | Unchanged |
| 9 | ZBIO | Zenas Biopharma Inc | +0.9% | — | Unchanged |
| 10 | TRVI | Trevi Therapeutics Inc | +0.8% | +13.52% | Add |
| 11 | RZLT | Rezolute Inc | +0.8% | — | Unchanged |
| 12 | VSTM | Verastem Inc | +0.7% | +71.92% | Add |
| 13 | AKRO | Akero Therapeutics Inc | +0.6% | — | Add |
| 14 | ✓ | Avadel Pharmaceuticals PLC ADR | +0.5% | — | Unchanged |
| 15 | OLMA | Olema Pharmaceuticals Inc | +0.4% | — | Unchanged |
| 16 | ERAS | Erasca Inc | +0.4% | +37.25% | Add |
| 17 | CRVS | Corvus Pharmaceuticals Inc | +0.4% | — | Unchanged |
| 18 | ETNBGBP | 89bio Inc | +0.1% | — | Unchanged |
| 19 | SLN | Silence Therapeutics Plc-adr | +0.1% | — | Unchanged |
| 20 | DTIL | Precision Biosciences Inc | — | — | Unchanged |
| 21 | VRDN | Viridian Therapeutics Inc | 0% | — | Unchanged |
| 22 | TENX | Tenax Therapeutics Inc | -0.1% | — | Unchanged |
| 23 | VRNA | Verona Pharma PLC - Adr | -0.1% | — | Trim |
| 24 | SRZN | Surrozen Inc | -0.1% | — | Unchanged |
| 25 | CATBUSD | Astria Therapeutics Inc | -0.2% | — | Unchanged |
| 26 | ABEO | Abeona Therapeutics Inc | -0.4% | — | Unchanged |
| 27 | SERA | Sera Prognostics Inc-a | -0.4% | — | Unchanged |
| 28 | ACRS | Aclaris Therapeutics Inc | -0.4% | — | Unchanged |
| 29 | DCTH | Delcath Systems Inc | -0.8% | — | Trim |
| 30 | TIL | Instil Bio Inc | -0.9% | — | Trim |
| 31 | GERN | Geron CORP | -2.7% | — | Unchanged |
| 32 | SLNOEUR | Soleno Therapeutics Inc | -29.8% | -42.44% | Trim |
| 33 | SVA | Sinovac Biotech Ltd. | — | NEW | New buy |
| 34 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 35 | SABS | Sab Biotherapeutics Inc | — | NEW | New buy |
| 36 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 37 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 38 | CAMP | Camp4 Therapeutics CORP | — | NEW | New buy |
| 39 | PEPG | Pepgen Inc | — | NEW | New buy |
| 40 | DBVT | Dbv Technologies Sa-spon Adr | — | NEW | New buy |
| 41 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 42 | CMPS | Compass Pathways PLC | — | EXIT | Sold out |
| 43 | CTMX | Cytomx Therapeutics Inc | — | NEW | New buy |
| 44 | EPRX | Eupraxia Pharmaceuticals Inc | — | NEW | New buy |
| 45 | UNCY | Unicycive Therapeutics Inc | — | NEW | New buy |
| 46 | MNPR | Monopar Therapeutics Inc | — | NEW | New buy |
| 47 | IOBTQ | Io Biotech Inc | — | EXIT | Sold out |
| 48 | ✓ | — | EXIT | Sold out | |
| 49 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 50 | CELC | Celcuity Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 47 disclosed positions in Q3 2025.
During Q3 2025, Vivo Capital, LLC's top holdings by market value included SLNOEUR (12.4%)、VRNA (12.0%)、CDTX (10.1%). The largest single position, SLNOEUR, represented 12.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
SVA
市值: $38.2M
Top Position Liquidated / Trimmed
CMPS
前期市值: $9.6M
In Q3 2025, Vivo Capital, LLC made 37 total portfolio adjustments, initiating 15 new buys, adding to 10 positions, trimming 4 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.